

Global Acute Coronary Syndrome Therapeutic Market Size study, by Drug Class (Antiplatelet Drugs, Beta-Blockers, Statins, ACE Inhibitors, Angiotensin II Receptor Blockers (ARBs), Antithrombotic Agents, Others), Type (Unstable Angina, NSTEMI, STEMI), Route of Administration (Oral, Injectable), End-User (Hospitals, ASCs, Specialty Clinics, Others) and Regional Forecasts 2022-2032

<https://marketpublishers.com/r/GC878FBFE724EN.html>

Date: May 2025

Pages: 285

Price: US\$ 3,218.00 (Single User License)

ID: GC878FBFE724EN

Abstracts

Global Acute Coronary Syndrome (ACS) Therapeutic Market is valued approximately at USD 8.38 billion in 2023 and is anticipated to grow with a healthy CAGR of more than 5.40% over the forecast period 2024-2032. Acute coronary syndrome, a term encompassing clinical manifestations like unstable angina and myocardial infarction, represents a leading cause of cardiovascular morbidity and mortality worldwide. Therapeutics in this market are designed to stabilize plaque, prevent clot formation, and manage the ischemic damage caused by reduced blood flow to the heart. Treatment strategies commonly integrate a combination of antiplatelet agents, beta-blockers, statins, and renin-angiotensin system inhibitors. This evolving clinical paradigm is increasingly shaped by real-world data, evidence-based guidelines, and the expanding role of personalized medicine in cardiovascular care.

The demand trajectory for acute coronary syndrome therapeutics is bolstered by several compelling factors. The global uptick in sedentary lifestyles, obesity, diabetes, and hypertension has dramatically escalated cardiovascular risks, particularly among the elderly. Coupled with early symptom recognition and heightened diagnostic capabilities, more patients are being funneled into treatment pathways earlier in the disease cycle.

Simultaneously, the pharmaceutical industry is pushing the boundaries of innovation—targeted oral anticoagulants, novel dual antiplatelet therapies, and biosimilars are entering the market, enhancing both efficacy and patient compliance. Healthcare policies are increasingly favoring value-based treatment models, encouraging wider therapeutic adoption.

However, the market's growth is tempered by several challenges. Medication adherence remains a persistent issue, especially in chronic cardiovascular management where polypharmacy is common. The high cost of branded medications, especially in low- and middle-income economies, restricts broad-scale access despite government interventions. Moreover, the intricate interplay of comorbidities such as renal impairment or diabetes complicates therapeutic decision-making. That said, the growing investment in generic drug development, coupled with the proliferation of public-private healthcare partnerships and improvements in cardiac care infrastructure, offers fertile ground for sustained market penetration.

Technology and treatment delivery mechanisms are also undergoing a metamorphosis. With a clear tilt toward patient-centricity, oral therapies are being optimized for once-daily dosing regimens, while injectable therapies are being reformulated for outpatient and home-use settings. This is simultaneously driving growth across distribution channels, with hospital pharmacies remaining dominant, but retail and online pharmacies gaining steady traction. The trend toward integrating digital health—such as remote monitoring of patient vitals and AI-based risk prediction—is transforming post-discharge care and medication titration, reinforcing the role of ACS therapeutics in long-term cardiovascular health management.

Geographically, North America leads the ACS therapeutic market, supported by sophisticated healthcare infrastructure, rapid adoption of novel therapies, and an aging population prone to cardiovascular events. Europe follows closely, benefiting from public health initiatives, coordinated care models, and reimbursement policies that support drug innovation. Meanwhile, Asia Pacific is anticipated to witness the fastest growth during the forecast period, driven by rising prevalence of cardiovascular diseases, expanding healthcare access, and government efforts to reduce non-communicable disease burden. Latin America and the Middle East & Africa are also catching up due to greater awareness, international funding for cardiac health, and the rollout of national cardiovascular programs.

Major market player included in this report are:

AstraZeneca PLC

Novartis AG

Sanofi S.A.

Merck & Co., Inc.

Bristol-Myers Squibb Company

Pfizer Inc.

Johnson & Johnson

Bayer AG

Amgen Inc.

Boehringer Ingelheim International GmbH

Teva Pharmaceutical Industries Ltd.

Eli Lilly and Company

GlaxoSmithKline plc

Daiichi Sankyo Company, Limited

Mylan N.V.

The detailed segments and sub-segment of the market are explained below:

By Drug Class

Antiplatelet Drugs

Beta-Blockers

Statins

ACE Inhibitors

Angiotensin II Receptor Blockers (ARBs)

Antithrombotic Agents

Others

By Type

Unstable Angina

Non-ST-Elevation Myocardial Infarction (NSTEMI)

ST-Elevation Myocardial Infarction (STEMI)

By Route of Administration

Oral

Injectable

By End-User

Hospitals

Ambulatory Surgical Centers (ASCs)

Specialty Clinics

Others

By Region:

North America

U.S.

Canada

Europe

UK

Germany

France

Spain

Italy

Rest of Europe

Asia Pacific

China

India

Japan

Australia

South Korea

Rest of Asia Pacific

Latin America

Brazil

Mexico

Rest of Latin America

Middle East & Africa

Saudi Arabia

South Africa

Rest of Middle East & Africa

Years considered for the study are as follows:

Historical year – 2022

Base year – 2023

Forecast period – 2024 to 2032

Key Takeaways:

Market Estimates & Forecast for 10 years from 2022 to 2032.

Annualized revenues and regional level analysis for each market segment.

Detailed analysis of geographical landscape with Country level analysis of major regions.

Competitive landscape with information on major players in the market.

Analysis of key business strategies and recommendations on future market approach.

Analysis of competitive structure of the market.

Demand side and supply side analysis of the market.

Companies Mentioned

AstraZeneca PLC

Novartis AG

Sanofi S.A.

Merck & Co., Inc.

Bristol-Myers Squibb Company

Pfizer Inc.

Johnson & Johnson

Bayer AG

Amgen Inc.

Boehringer Ingelheim International GmbH

Teva Pharmaceutical Industries Ltd.

Eli Lilly and Company

GlaxoSmithKline plc

Daiichi Sankyo Company, Limited

Mylan N.V.

Contents

CHAPTER 1. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET EXECUTIVE SUMMARY

- 1.1. Global Acute Coronary Syndrome Therapeutic Market Size & Forecast (2022–2032)
- 1.2. Regional Summary
- 1.3. Segmental Summary
 - 1.3.1. By Drug Class
 - 1.3.2. By Type
 - 1.3.3. By Route of Administration
 - 1.3.4. By End-User
- 1.4. Key Trends
- 1.5. Recession Impact
- 1.6. Analyst Recommendation & Conclusion

CHAPTER 2. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET DEFINITION AND RESEARCH ASSUMPTIONS

- 2.1. Research Objective
- 2.2. Market Definition
- 2.3. Research Assumptions
 - 2.3.1. Inclusion & Exclusion
 - 2.3.2. Limitations
 - 2.3.3. Supply Side Analysis
 - 2.3.3.1. Availability
 - 2.3.3.2. Infrastructure
 - 2.3.3.3. Regulatory Environment
 - 2.3.3.4. Market Competition
 - 2.3.3.5. Economic Viability (Consumer's Perspective)
 - 2.3.4. Demand Side Analysis
 - 2.3.4.1. Regulatory Frameworks
 - 2.3.4.2. Technological Advancements
 - 2.3.4.3. Environmental Considerations
 - 2.3.4.4. Consumer Awareness & Acceptance
- 2.4. Estimation Methodology
- 2.5. Years Considered for the Study
- 2.6. Currency Conversion Rates

CHAPTER 3. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET DYNAMICS

3.1. Market Drivers

- 3.1.1. Rising Prevalence of Cardiovascular Risk Factors
- 3.1.2. Enhanced Early Diagnosis and Biomarker Profiling
- 3.1.3. Introduction of Novel Antithrombotic and Antiplatelet Therapies

3.2. Market Challenges

- 3.2.1. Medication Adherence and Polypharmacy Issues
- 3.2.2. High Cost of Branded Therapies in Emerging Economies

3.3. Market Opportunities

- 3.3.1. Expansion of Generic and Biosimilar Offerings
- 3.3.2. Growth of Digital Health–Enabled Cardiac Care
- 3.3.3. Increasing Public–Private Partnerships for Cardiac Programs

CHAPTER 4. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET INDUSTRY ANALYSIS

4.1. Porter's 5 Force Model

- 4.1.1. Bargaining Power of Suppliers
- 4.1.2. Bargaining Power of Buyers
- 4.1.3. Threat of New Entrants
- 4.1.4. Threat of Substitutes
- 4.1.5. Competitive Rivalry
- 4.1.6. Futuristic Approach to Porter's 5 Forces
- 4.1.7. Porter's 5 Forces Impact Analysis

4.2. PESTEL Analysis

- 4.2.1. Political
- 4.2.2. Economical
- 4.2.3. Social
- 4.2.4. Technological
- 4.2.5. Environmental
- 4.2.6. Legal

4.3. Top Investment Opportunity

4.4. Top Winning Strategies

4.5. Disruptive Trends

4.6. Industry Expert Perspective

4.7. Analyst Recommendation & Conclusion

CHAPTER 5. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE & FORECASTS BY DRUG CLASS 2022–2032

- 5.1. Segment Dashboard
- 5.2. Revenue Trend Analysis by Drug Class, 2022 & 2032 (USD Billion)
 - 5.2.1. Antiplatelet Drugs
 - 5.2.2. Beta-Blockers
 - 5.2.3. Statins
 - 5.2.4. ACE Inhibitors
 - 5.2.5. Angiotensin II Receptor Blockers (ARBs)
 - 5.2.6. Antithrombotic Agents
 - 5.2.7. Others

CHAPTER 6. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE & FORECASTS BY TYPE 2022–2032

- 6.1. Segment Dashboard
- 6.2. Revenue Trend Analysis by Type, 2022 & 2032 (USD Billion)
 - 6.2.1. Unstable Angina
 - 6.2.2. Non-ST-Elevation Myocardial Infarction (NSTEMI)
 - 6.2.3. ST-Elevation Myocardial Infarction (STEMI)

CHAPTER 7. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE & FORECASTS BY ROUTE OF ADMINISTRATION 2022–2032

- 7.1. Segment Dashboard
- 7.2. Revenue Trend Analysis by Route of Administration, 2022 & 2032 (USD Billion)
 - 7.2.1. Oral
 - 7.2.2. Injectable

CHAPTER 8. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE & FORECASTS BY END-USER 2022–2032

- 8.1. Segment Dashboard
- 8.2. Revenue Trend Analysis by End-User, 2022 & 2032 (USD Billion)
 - 8.2.1. Hospitals
 - 8.2.2. Ambulatory Surgical Centers (ASCs)
 - 8.2.3. Specialty Clinics

8.2.4. Others

CHAPTER 9. GLOBAL ACUTE CORONARY SYNDROME THERAPEUTIC MARKET SIZE & FORECASTS BY REGION 2022–2032

9.1. North America Market

9.1.1. U.S.

9.1.1.1. Drug Class breakdown size & forecasts, 2022–2032

9.1.1.2. Type breakdown size & forecasts, 2022–2032

9.1.1.3. Route of Administration breakdown size & forecasts, 2022–2032

9.1.1.4. End-User breakdown size & forecasts, 2022–2032

9.1.2. Canada

9.2. Europe Market

9.2.1. UK

9.2.2. Germany

9.2.3. France

9.2.4. Spain

9.2.5. Italy

9.2.6. Rest of Europe

9.3. Asia Pacific Market

9.3.1. China

9.3.2. India

9.3.3. Japan

9.3.4. Australia

9.3.5. South Korea

9.3.6. Rest of Asia Pacific

9.4. Latin America Market

9.4.1. Brazil

9.4.2. Mexico

9.4.3. Rest of Latin America

9.5. Middle East & Africa Market

9.5.1. Saudi Arabia

9.5.2. South Africa

9.5.3. Rest of Middle East & Africa

CHAPTER 10. COMPETITIVE INTELLIGENCE

10.1. Key Company SWOT Analysis

10.1.1. AstraZeneca PLC

- 10.1.2. Novartis AG
- 10.1.3. Sanofi S.A.
- 10.2. Top Market Strategies
- 10.3. Company Profiles
 - 10.3.1. AstraZeneca PLC
 - 10.3.1.1. Key Information
 - 10.3.1.2. Overview
 - 10.3.1.3. Financial (Subject to Data Availability)
 - 10.3.1.4. Product Summary
 - 10.3.1.5. Market Strategies
 - 10.3.2. Novartis AG
 - 10.3.3. Sanofi S.A.
 - 10.3.4. Merck & Co., Inc.
 - 10.3.5. Bristol-Myers Squibb Company
 - 10.3.6. Pfizer Inc.
 - 10.3.7. Johnson & Johnson
 - 10.3.8. Bayer AG
 - 10.3.9. Amgen Inc.
 - 10.3.10. Boehringer Ingelheim International GmbH
 - 10.3.11. Teva Pharmaceutical Industries Ltd.
 - 10.3.12. Eli Lilly and Company
 - 10.3.13. GlaxoSmithKline plc
 - 10.3.14. Daiichi Sankyo Company, Limited
 - 10.3.15. Mylan N.V.

CHAPTER 11. RESEARCH PROCESS

- 11.1. Research Process
 - 11.1.1. Data Mining
 - 11.1.2. Analysis
 - 11.1.3. Market Estimation
 - 11.1.4. Validation
 - 11.1.5. Publishing
- 11.2. Research Attributes

List Of Tables

LIST OF TABLES

TABLE 1. Global Acute Coronary Syndrome Therapeutic market, report scope
TABLE 2. Market estimates & forecasts by Region 2022–2032 (USD Billion)
TABLE 3. Estimates & forecasts by Drug Class 2022–2032 (USD Billion)
TABLE 4. Estimates & forecasts by Type 2022–2032 (USD Billion)
TABLE 5. Estimates & forecasts by Route of Administration 2022–2032 (USD Billion)
TABLE 6. Estimates & forecasts by End-User 2022–2032 (USD Billion)
TABLE 7. Market by segment, estimates & forecasts, 2022–2032 (USD Billion)
TABLE 8. U.S. market estimates & forecasts, 2022–2032 (USD Billion)
TABLE 9. Canada market estimates & forecasts, 2022–2032 (USD Billion)
TABLE 10. Europe market estimates & forecasts by country, 2022–2032 (USD Billion)
TABLE 11. Asia Pacific market estimates & forecasts by country, 2022–2032 (USD Billion)
TABLE 12. Latin America market estimates & forecasts by country, 2022–2032 (USD Billion)
TABLE 13. Middle East & Africa market estimates & forecasts by country, 2022–2032 (USD Billion)
TABLE 14. Competitive landscape 2023 (market share %)
TABLE 15. Pricing analysis by region (2023)
TABLE 16. Treatment cost comparison by Drug Class
TABLE 17. Patient adherence rates by Route of Administration
TABLE 18. R&D pipeline summary 2023
TABLE 19. Key FDA/EU approvals 2022–2023
TABLE 20. Public–Private partnership initiatives overview

List Of Figures

LIST OF FIGURES

- FIG 1. Research methodology
- FIG 2. Market estimation techniques
- FIG 3. Global market size estimates & forecast methods
- FIG 4. Key trends 2023
- FIG 5. Growth prospects 2022–2032
- FIG 6. Porter's 5 Forces model
- FIG 7. PESTEL analysis
- FIG 8. Value chain analysis
- FIG 9. Market by segment, 2022 & 2032 (USD Billion)
- FIG 10. Regional snapshot 2022 & 2032 (USD Billion)
- FIG 11. North America market 2022 & 2032 (USD Billion)
- FIG 12. Europe market 2022 & 2032 (USD Billion)
- FIG 13. Asia Pacific market 2022 & 2032 (USD Billion)
- FIG 14. Latin America market 2022 & 2032 (USD Billion)
- FIG 15. Middle East & Africa market 2022 & 2032 (USD Billion)
- FIG 16. Company market share analysis (2023)
- FIG 17. Distribution channel share analysis (2023)
- FIG 18. Pricing trend 2022–2032
- FIG 19. R&D investment heatmap
- FIG 20. Digital health integration framework

I would like to order

Product name: Global Acute Coronary Syndrome Therapeutic Market Size study, by Drug Class (Antiplatelet Drugs, Beta-Blockers, Statins, ACE Inhibitors, Angiotensin II Receptor Blockers (ARBs), Antithrombotic Agents, Others), Type (Unstable Angina, NSTEMI, STEMI), Route of Administration (Oral, Injectable), End-User (Hospitals, ASCs, Specialty Clinics, Others) and Regional Forecasts 2022-2032

Product link: <https://marketpublishers.com/r/GC878FBFE724EN.html>

Price: US\$ 3,218.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GC878FBFE724EN.html>